Table 1.
Baseline characteristics
| Baseline characteristics (n = 28) | % (n) |
|---|---|
| Age (median) (y) | 72 (51-94) |
| Gender (male) | 68 (19) |
| Race (White) | 96 (27) |
| MDS classification WHO 2016 | |
| MDS-SLD | 10.7 (3) |
| MDS-MLD | 10.7 (3) |
| MDS-SLD-RS | 32.1 (9) |
| MDS-MLD-RS | 21.4 (6) |
| MDS del 5q | 3.6 (1) |
| MDS/MPN-RS-T | 21.4 (6) |
| R-IPSS | |
| Very low | 21.4 (6) |
| Low | 67.9 (19) |
| Intermediate | 7.1 (2) |
| High | 3.6 (1) |
| Hgb (mean) g/dL | 8 (6.6-9.4) |
| Platelets (mean) × 109/L | 259 (16-814) |
| ANC (mean) × 109/L | 2.53 (.45-9.1) |
| Myeloblasts % (mean) | 2 (0-4) |
| Serum erythropoietin level (median) U/L | 119.5 (n = 18) |
| RBC TB | |
| NTD | 11 (3) |
| LTB | 46 (13) |
| HTB | 43 (12) |
| Previous ESA treatment | 89 (24) |
| Previous HMA treatment | 42 (12) |
| Previous lenalidomide treatment | 39 (11) |
| Somatic mutations | |
| SF3B1 | 85.7 (24) |
| TET-2 | 44 (12/27) |
| DNMT3A | 22 (6/27) |
| ASXL-1 | 4 (1/27) |
| TP53 | 4 (1/27) |
| JAK-2 | 12 (3/27) |
ANC, absolute neutrophil count; MLD, multi-lineage dysplasia; MPN myeloproliferative neoplasm; SLD, single lineage dysplasia.